Kuros Biosciences AG

OTCPK:CSBT.F Stock Report

Market Cap: US$1.1b

Kuros Biosciences Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Chris Fair

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage36.75%
CEO tenure2.8yrs
CEO ownershipn/a
Management average tenure2.8yrs
Board average tenure7.9yrs

Recent management updates

Recent updates

New Narrative • Jul 26

How a Mispriced Medtech Engine is Disrupting $5,000 Bone Graft Giants.

Wall Street and retail investors routinely misprice Kuros Biosciences by lumping it into the speculative, cash-burning biotech basket. In reality, Kuros has transformed into a high-margin Medtech commercial powerhouse delivering ~80%+ YoY sales growth with ~80%+ Gross Margins and expanding operating profitability.

CEO Compensation Analysis

How has Chris Fair's remuneration changed compared to Kuros Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025US$1mUS$521k

US$2m

Sep 30 2025n/an/a

-US$2m

Jun 30 2025n/an/a

-US$7m

Mar 31 2025n/an/a

-US$5m

Dec 31 2024US$4mUS$440k

-US$4m

Jun 30 2024n/an/a

-US$6m

Mar 31 2024n/an/a

-US$8m

Dec 31 2023US$2mUS$391k

-US$12m

Sep 30 2023n/an/a

-US$16m

Jun 30 2023n/an/a

-US$18m

Mar 31 2023n/an/a

-US$17m

Dec 31 2022US$39kn/a

-US$16m

Sep 30 2022n/an/a

-US$13m

Jun 30 2022n/an/a

-US$12m

Mar 31 2022n/an/a

-US$10m

Dec 31 2021US$39kn/a

-US$8m

Compensation vs Market: Chris's total compensation ($USD1.42M) is below average for companies of similar size in the US market ($USD3.61M).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.

CEO

Chris Fair (56 yo)

2.8yrs
Tenure
US$1,416,597
Compensation

Mr. Christopher T. Fair, also known as Chris, B.B.A., serves as the Chief Executive Officer At Kuros Biosciences AG since October 2023 and serves as Director since April 17, 2024. He was the Chief Operatin...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Fair
CEO & Director2.8yrsUS$1.42mno data
Daniel Geiger
Chief Financial Officer3.3yrsno datano data
Joost de Bruijn
President of Innovation and Strategy & Executive Director2.8yrsno data1.13%
$ 12.5m
Sjoerd Musters
Executive Officerless than a yearno datano data
Harry Hall
Chief Operating Officerless than a yearno datano data
G. Ross
Senior Vice President of Marketing & Business Development2.6yrsno datano data
Laura Rosa
Senior Vice President of Global Human Resources1.6yrsno datano data
Philippe Saudan
Senior Vice President of Quality10yrsno datano data
John Griffin
Chief Business Officer8.3yrsno datano data
Carly Dummer
Senior Director of Marketingno datano datano data
Virginia Jamieson
Consultant8.3yrsno datano data
2.8yrs
Average Tenure
58yo
Average Age

Experienced Management: CSBT.F's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christopher Fair
CEO & Director2.3yrsUS$1.42mno data
Joost de Bruijn
President of Innovation and Strategy & Executive Director8.2yrsno data1.13%
$ 12.5m
Clemens van Blitterswijk
Chairman9.2yrsUS$255.50k0.84%
$ 9.3m
Oliver Walker
Independent Non-Executive Director8.2yrsUS$178.62k0.029%
$ 318.9k
Cato Laurentin
Member of Advisory Boardno datano datano data
Ralph Müller
Member of Advisory Boardno datano datano data
Norbert Boos
Member of Advisory Boardno datano datano data
Thomas Steffen
Member of Advisory Boardno datano datano data
Kimberley Elting
Director1.3yrsUS$138.23kno data
Richard Allen
Member of Strategic Advisory Board7.9yrsno datano data
Alpesh Patel
Member of Strategic Advisory Board7.9yrsno datano data
Kornelis Poelstra
Member of Strategic Advisory Board7.9yrsno datano data
7.9yrs
Average Tenure
60yo
Average Age

Experienced Board: CSBT.F's board of directors are considered experienced (7.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/03 17:15
End of Day Share Price 2026/07/08 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kuros Biosciences AG is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Volker BosseBaader Helvea Equity Research
Thomas MeyerBaader Helvea Equity Research
Christian EhmannBerenberg